Replies to post #128103 on Biotech Values

[Regulardoc]

One of SNY's arguments against generic enoxaparin had been that it was impossible to characterize. While I cannot recall the exact date, there was a filing or letter with the FDA several years ago, perhaps by Ram, that mentioned that SNY admitted that they had only characterized about 76-80% of the drug (or thereabouts).